Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $16,673.24 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.92, for a total value of $16,673.24. Following the sale, the director owned 24,681 shares in the company, valued at approximately $516,326.52. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN PTHS traded up $3.98 during trading hours on Monday, reaching $24.38. The stock had a trading volume of 28,715 shares, compared to its average volume of 8,812. The company has a market capitalization of $81.92 million, a P/E ratio of -1.17 and a beta of 3.93. Pelthos Therapeutics Inc. has a twelve month low of $9.00 and a twelve month high of $54.29. The stock has a fifty day moving average price of $22.86. The company has a current ratio of 2.05, a quick ratio of 1.15 and a debt-to-equity ratio of 0.81.

Analyst Ratings Changes

A number of equities analysts have recently commented on PTHS shares. Roth Mkm reduced their price objective on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Piper Sandler started coverage on Pelthos Therapeutics in a report on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Oppenheimer raised their target price on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, March 20th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $55.00.

Institutional Investors Weigh In On Pelthos Therapeutics

Hedge funds have recently made changes to their positions in the company. Persistent Asset Partners Ltd lifted its holdings in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the last quarter. Millennium Management LLC bought a new stake in Pelthos Therapeutics during the fourth quarter worth about $343,000. Geode Capital Management LLC increased its holdings in shares of Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares in the last quarter. Knott David M Jr raised its stake in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after acquiring an additional 13,169 shares during the last quarter. Finally, Diadema Partners LP boosted its holdings in shares of Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares in the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).